NCT05325203View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

PHASE3CompletedINTERVENTIONAL

Enrollment

135

Participants

Timeline

Start Date

December 31, 2021

Primary Completion Date

May 8, 2023

Study Completion Date

June 29, 2023

Conditions

Heterozygous Familial Hypercholesterolemia

Interventions

BIOLOGICAL

Ongericimab

Administered by subcutaneous injection

DRUG

Placebo

Administered by subcutaneous injection

Trial Locations (1)

100020

Beijing Anzhen Hospital Capital Medical University City:Beijing, Beijing

All Listed Sponsors

lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT05325203 - A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH). | Biotech Hunter | Biotech Hunter